Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Thalassemia and Treatment

The Thalassemia Channel on VJHemOnc is supported by Agios Pharmaceuticals. The supporter has no influence over the production of the content.

View overview page
1:08
Bone Marrow Quality Index to assess the safety of HSCT in thalassemia
Lawrence Faulkner • 26 Oct 2023
3:13
Treating SCD and thalassemia, and the need for early diagnosis and access to treatment
Baba Inusa • 27 Oct 2023
3:26
Improved life expectancy of patients with thalassemia and the challenges this presents
Maria Domenica Cappellini • 27 Oct 2023
2:23
The current landscape of thalassemia treatment
Subarna Chakravorty • 26 Oct 2023
1:59
The importance of ASCAT 2023
Baba Inusa • 27 Oct 2023
2:30
Cure2Children: delivering transplant therapy for SCD and thalassemia in developing countries
Lawrence Faulkner • 26 Oct 2023
3:03
ASCAT 2023: goals and current projects
Baba Inusa • 27 Oct 2023
2:02
BEYOND trial update: luspatercept in non-transfusion-dependent β-thalassemia
Ali Taher • 16 Jun 2023
2:09
Past, present, and future management strategies for non-transfusion dependent β-thalassemia
Ali Taher • 16 Jun 2023
8:19
CLIMB Thal-111 & CLIMB SCD-121: TI and elimination of VOCs after exa-cel in TDT and SCD
Franco Locatelli • 9 Jun 2023
3:04
Session highlights: top abstracts in red cell disorders
Subarna Chakravorty • 24 Apr 2023
1:53
Synergistic combination of RAP-GRL & TMPRSS6-ASO in β-thalassemia
Stefano Rivella • 11 Dec 2022
1:11
Novel mouse model to investigate the pathophysiology of alpha-thalassemia
Stefano Rivella • 11 Dec 2022
2:13
Nursing track: pharmacy updates
Susie Long • 9 Feb 2023
2:13
Insights into the mechanism of action and applications of mitapivat
Hanny Al-Samkari • 11 Dec 2022
12:53
Long-term outcomes of patients with TDT treated with beti-cel
Franco Locatelli • 10 Dec 2022

The Thalassemia Channel on VJHemOnc is supported by Agios Pharmaceuticals.

The supporter has no influence over the production of the content.

If you are interested in becoming a supporter of The Non-Malignant Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals